Entera Bio and OPKO Health Provide Update on PK/PD Results of Oral Oxyntomodulin (GLP-1/Glucagon) Peptide Tablet Candidate for Obesity and Metabolic Disorders
25 sept. 2024 08h30 HE
|
Entera Bio Ltd.; OPKO Health, Inc.
JERUSALEM and MIAMI, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (Entera), a leader in the development of orally delivered peptides, and OPKO Health, Inc. (NASDAQ: OPK) (OPKO)...
Glucosamine Market and Glucagon Market Overview 2022: Leading Players Updates, Consumer-Demand Status, Consumption, Recent Developments, Business Strategies, Market Pulse, Screener , Indexes, Impact & Forecast till 2027 | Industry Research
03 févr. 2022 14h35 HE
|
Industry Research
Pune, Feb. 04, 2022 (GLOBE NEWSWIRE) -- Global Glucosamine Market Analysis and Insights: The global Glucosamine market was valued at USD 231.9 million in 2020 and it is expected to reach USD 304.8...
泵给药短效多激素组合专利申请将Adocia临床研究扩展到肥胖症领域
26 mai 2021 01h30 HE
|
Adocia SA
已申请三项专利系列涵盖新型激素组合：普兰林肽-艾塞那肽和胰高血糖素-艾塞那肽——两种组合在肥胖症治疗中均显示出令人鼓舞的效果通过泵输注短效激素可以增强患者授权，使患者可以优化治疗的获益/风险比这些配方也可以用于治疗其他代谢性疾病，例如NASH（非酒精性脂肪性肝炎），2型糖尿病或神经退行性疾病 里昂, May 26, 2021 (GLOBE NEWSWIRE) -- Adocia...
Adocia Expands Clinical Development to Obesity with Patent Applications on Short-Acting Multihormonal Combinations Administered by Pumps
26 mai 2021 01h30 HE
|
Adocia SA
Three patent families have been filed to cover novel hormonal combinations: pramlintide-exenatide and glucagon-exenatide – both combinations demonstrated promising effects in obesity...
Xeris Pharmaceuticals, Inc. Completes $55 million In New Financing To Support Ready-To-Use Glucagon Development
08 mars 2018 18h00 HE
|
Xeris Pharmaceuticals, Inc.
CHICAGO, IL, March 08, 2018 (GLOBE NEWSWIRE) --
CHICAGO, IL; March 8, 2018 (GLOBE NEWSWIRE) – Xeris Pharmaceuticals, Inc. (“Xeris”), a specialty pharmaceutical company leveraging its novel...
Xeris Pharmaceuticals Achieves Phase 3 Milestones of its Ready-to-Use Glucagon Rescue Pen for the Treatment of Severe Hypoglycemia
15 févr. 2018 17h00 HE
|
Xeris Pharmaceuticals, Inc.
Chicago, IL, Feb. 15, 2018 (GLOBE NEWSWIRE) --
Xeris Pharmaceuticals, Inc. (“Xeris”), a specialty pharmaceutical company leveraging its novel technology platforms to develop and...
Xeris Pharmaceuticals, Inc. Appoints John P. Schmid to Board of Directors
07 sept. 2017 16h30 HE
|
Xeris Pharmaceuticals, Inc.
Chicago, IL and Austin, TX, Sept. 07, 2017 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc., a specialty biopharmaceutical company developing improved and differentiated injectable therapeutics for...
Xeris Pharmaceuticals Announces New Results From Ready-To-Use Liquid Glucagon Clinical Development Program
16 juin 2017 07h51 HE
|
Xeris Pharmaceuticals, Inc.
CHICAGO, IL and AUSTIN, TX, June 16, 2017 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (“Xeris”) announced today that results from three clinical studies of the company’s investigational...
Xeris Pharmaceuticals’ Ready-to-Use Liquid Glucagon Clinical Data to Be Presented at American Diabetes Association 77th Scientific Sessions
05 juin 2017 08h15 HE
|
Xeris Pharmaceuticals, Inc.
CHICAGO, IL and AUSTIN, TX; , June 05, 2017 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (“Xeris”) today announced that data from the company’s non-aqueous, room temperature stable, ready to use...
Xeris Pharmaceuticals Announces Closing of $30 Million Financing
17 mai 2017 19h00 HE
|
Xeris Pharmaceuticals, Inc.
CHICAGO, IL and AUSTIN, TX, May 17, 2017 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc., a specialty biopharmaceutical company focused on the development and commercialization of novel formulations...